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Introduction: Ultrasound (US) assessment of joints is an evolving point of care tool for the 
detection of early joint arthropathy (Napolitano M, Kessler CM. Hemophilia A and B. 
Consultative Hemostasis and Thrombosis, Kitchens, 4th edition); population 
pharmacokinetic (pop-PK) studies are adopted as a useful instrument to set the 
prophylaxis regimen for patients with hemophilia, they may improve adherence (Nagao 
A.et al. Thromb Res. 2019 Jan; 173:79-84) and reduce the annual bleeding rate (ABR). 
Adherence to continuous intravenous administrations of factor VIII or Factor IX products is 
challenging, thus patients may experience breakthrough bleedings while on prophylaxis. 
Repeated US examinations of joint status have recently been advocated to attempt to 
remedy sub-optimal medication adherence (Di Minno A et al., Blood Rev. 2019 
Jan;33:106-116). Aim of the current prospective analysis was to evaluate the impact of 
combined US assessment and pop-PK study on adherence to treatment and health related 
quality of life in patients with severe hemophilia A(HA) and B (HB) under regular 
prophylaxis. 
Material and methods: This prospective observational study was performed at a single 
tertiary center from January 2017 to June 2019. Research was conducted following the 
Helsinki Declaration. All patients included in the study provided a written informed consent 
for study participation. Patients with severe HA and HB routinely underwent, as part of 
regular 12-months follow-up visits, the following: US joints evaluation of elbows, knees and 
ankles using the HEAD-US protocol, treatment adherence evaluation by VERITAS-Pro 
questionnaire, health -related quality of life assessment by the standardized EQ-5D,EQ-
VAS and pop-PK study (WAPPS-Hemo, McMaster University) as needed (i.e.in case of 
changes in life style, planned treatment switch); each patient visualised US and his 
estimated PK profile during medial encounters. Compliance to the prescribed treatment 
was also determined by analysis of patient diaries with infusion logs. Statistical analysis 
was performed using the SPSS software version 25.0 (SPSS Chicago, IL). Statistical tests 
were 2-sided, with a significance threshold of 0.05. 
Results: Twenty consecutive males with severe haemophilia were included in the current 
analysis, 13 with severe HA, 2 with HA with previous inhibitors and 5 HB, with a median 
age of 30 (range 14- 56) years and a median ABR of 5 (range:0-12). Nine patients were 
under primary prophylaxis, 8 under secondary prophylaxis and 3 under tertiary 
prophylaxis, they all self-infused at home. Four patients had one target joint and 3 patients 
had multiple target joints. For each enrolled subject, HEAD-US score, VERITAS-pro, 
EQ5D and EQ-VAS score were assessed at enrolment (T0) and at 12 (T12) and 24 (T24) 
months follow-up visits, respectively. Pop-PK was assessed in 11 patients: in 7 (5 HA,2 
HB) it was assessed twice, before and after treatment switch to extended half-life (EHL) 
products, in 4 it was assessed once to modify prophylaxis treatment schedules for a more 
active life-style (N=2) or weight changes (N=2). Median ABR was 4 at T12 and 3.8 at T24. 
Reported breakthrough bleeds at T12 were 14, mainly trauma-related (N= 8) or affecting 
target joints (N=4), they were not reported at T24 in patients with PK-driven modified 
schedules (N=4) and in 4 patients under EHL treatments. Mean HEAD-US score at T0 
resulted 8 (range:0-16), at T24 it was 6 (range:0-16). Mean Veritas-Pro score values were 
42.7 at TO, 40.1 at T12 and 38.7 at T24. At T0, EQ-5D mean utility score was 0.82 (range: 
0.68-1), at T24, the mean was 0.87 (range:0.72-1). In detail, at 24 months follow-up, there 
was a statistically significant (p<0.05) improvement in adherence to treatment with 
particular reference to the dimensions of communication and skipped doses. A tendency 
toward improved HEAD-US score, higher adherence and better quality of life scores, was 
observed in particular in patients switched to EHL products at T24, at a mean of 10 
months after switching (range: 6-22 months). 
Conclusion: Several combined measures of haemophilia treatment monitoring, allowing 
visual assessment of joints status and PK profile estimates by patients have here shown to 
improve treatment adherence and quality of life in patients with HA and HB, this may be 
not only related to new available treatments but also to an increased awareness and 
education of patients. 
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